Evidence map›Paper›PMID 40512647›Full record

Trial reportInternational wound journal2025

The Potential Role for a Painless Enzymatic Debridement Gel in Wound Bed Preparation for Venous Leg Ulcers-A Dose Escalation Study.

David Goldsmith, David M Fairlamb

Abstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in International wound journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David GoldsmithSolasCure Limited, Cambridge, UK.ORCID https://orcid.org/0000-0002-4349-9193
David M FairlambSolasCure Limited, Cambridge, UK.ORCID https://orcid.org/0000-0002-3675-2437

Funding

SolasCure Ltd
6 · The paper itself

Abstract

Venous leg ulcers (VLUs) are painful wounds that require thorough debridement to optimise their chances of healing. We sought to assess the impact on debridement pain from the use of tarumase gel in a prospective Phase IIA open-label, multi-centre, dose escalation study and comparing this to historical pain scores derived from a review of surgical and mechanical debridement within similar chronic wound populations. With tarumase gel, no increase in pain over baseline was observed, irrespective of whether pain was assessed 15-30 min after administration or whether the gel had been resident on the wound for 48-72 h. At the highest concentration of tarumase tested [11 U/mL], all reported NRS scores were below 2.90 (categorised as slight pain) with small trends towards a reduction in the pain score from as early as the first application. By contrast, from previous literature, surgical and mechanical debridement, when used without anaesthesia, commonly resulted in pain scores in excess of 50 mm on 100 mm visual analogue scales (VAS), categorised as moderate to severe pain. Pain from surgical/mechanical debridement can be reduced by topical anaesthetic creams; however, this requires at least 30-60 min of application and subsequent removal prior to debridement, making it impractical to use in busy clinic facilities.

Indexed as

DebridementPainVaricose UlcerWound HealingAdultAgedAged, 80 and overFemaleGelsHumansMaleMiddle AgedPain MeasurementProspective StudiesTreatment OutcomeGelsenzymatic debridementsurgical debridementvenous leg ulcerswound pain

Identifiers

PMID40512647
PMCPMC12164925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.